References
- Catenacci DVT, Kozloff M, Kindler HL, Polite B. Personalized colon cancer care in 2010. Semin. Oncol.38(2), 284–308 (2011).
- Mariotto AB, Robin Yabroff K, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010–2020. J. Natl Cancer Inst.103(2), 117–128 (2011).
- Levêque D. Off-label use of anticancer drugs. Lancet Oncol.9(11), 1102–1107 (2008).
- Tversky A, Kahneman D. Judgment under uncertainty: heuristics and biases. Science185(4157), 1124–1131 (1974).
- Torke A, Siegler M, Abalos A, Moloney R, Alexander G. Physicians’ experience with surrogate decision making for hospitalized adults. J. Gen. Intern. Med.24(9), 1023–1028 (2009).
- Emanuel EJ, Fuchs VR. The perfect storm of overutilization. JAMA299(23), 2789–2791 (2008).
- Jacobson M, O’Malley AJ, Earle CC, Pakes J, Gaccione P, Newhouse JP. Does reimbursement influence chemotherapy treatment for cancer patients? Health Aff.25(2), 437–443 (2006).
- Danzon PM, Taylor E. Drug pricing and value in oncology. Oncologist15(Suppl. 1), 24–31 (2010).
- Smith TJ, Hillner BE. Concrete options and ideas for increasing value in oncology care: the view from one trench. Oncologist15(Suppl. 1), 65–72 (2010).
- Neugut AI, Becker DJ, Buono D, Kershenbaum A, Hershman DL. Off-label and approved use of bevacizumab in elderly patients with colon cancer. J. Clin. Oncol.28(15 Suppl.), e14038 (2010).
- Love N, Meropol NJ, Ravdin PM et al. Which adjuvant systemic treatments (AdjRx) would medical oncologists (MOs) wish to receive if they had colon cancer (CCa)? A survey of 150 physicians. J. Clin. Oncol.26(15 Suppl.), 4049 (2008).
- Allegra CJ, Yothers G, O’Connell MJ et al. Initial safety report of NSABP C-08: a randomized Phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with Stage II or III colon cancer. J. Clin. Oncol.27(20), 3385–3390 (2009).
- Zafar Y, Goetzinger AM, Fowler R et al. Impact of out-of-pocket expenses on cancer care. ASCO Meeting Abstracts29(15 Suppl.) (2011) (Abstract 6006).
- Ramsey SD, Fedorenko CR, Snell KS, Kirchhoff AC, Hollingworth W, Blough DK. Cancer diagnosis as a risk factor for personal bankruptcy. ASCO Meeting Abstracts29(15 Suppl.) (2011) (Abstract 6007).
- Grothey A, Sugrue MM, Purdie DM et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J. Clin. Oncol.26(33), 5326–5334 (2008).
- Hess GP, Wang PF, Quach D, Barber B, Zhao Z. Systemic therapy for metastatic colorectal cancer: patterns of chemotherapy and biologic therapy use in US medical oncology practice. J. Oncol. Pract.6(6), 301–307 (2010).
- Schilsky RL. Accrual to cancer clinical trials in the era of molecular medicine. Sci. Transl. Med.3(75), 75cm9 (2011).
- Temel JS, Greer JA, Muzikansky A et al. Early palliative care for patients with metastatic non–small-cell lung cancer. N. Engl. J. Med.363(8), 733–742 (2010).
- Goozner M. United Healthcare, five oncology practices try bundled payments. J. Natl Cancer Inst.103(1), 8–10 (2011).
Websites
- Definition of heuristic. 2011. In Merriam-Webster.com www.merriam-webster.com/dictionary/heuristic (Accessed 10 July 2011)
- Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) or Bevacizumab (NSC-704865) as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with either FOLFOX, OPTIMOX, or XELOX www.swog.org/Visitors/ViewProtocolDetails.asp?ProtocolID=2057 (Accessed 19 July 2011)